No Data
Express News | CEL-SCI Corp: On November 13, Patricia B Prichep Has Assumed the Duties of Chief Financial and Operations Officer
CEL-SCI, FDA Agree on Phase 3 Trial Design for Cancer Drug
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
Express News | CEL-SCI Corp Files Prospectus Relates to Possible Resale, From Time to Time, by Selling Shareholder of up to 1 Mln Shares of Common Stock
CEL-SCI Announces The Potential Impact On The Clinical Development Of Its Immunotherapy Multikine Resulting From A Recent U.S. FDA Oncologic Drugs Advisory Committee Meeting; Multikine Has Shown Survival Benefit And Favorable Safety Profile In A...
FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine to Address Major Treatment Gap for PD-L1 Negative Cancer Patients